{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:55:59Z","timestamp":1790898959952,"version":"4.1.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"vor","delay-in-days":225,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The most frequently reported treatment-related adverse event in clinical trials with the cyclin-dependent kinase 4\/6 (CDK4\/6) inhibitor palbociclib is neutropenia. Allelic variants in ABCB1 and ERCC1 might be associated with early occurrence (i.e., end of week 2 treatment) of grade 3\/4 neutropenia. Pharmacogenetic analyses were performed to uncover associations between single nucleotide polymorphisms (SNPs) in these genes, patient baseline characteristics, and early occurrence of grade 3\/4 neutropenia.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>ABCB1 (rs1045642, rs1128503) and ERCC1 (rs3212986, rs11615) were analyzed in germline DNA from palbociclib-treated patients from PALOMA-2 (n =\u2009584) and PALOMA-3 (n =\u2009442). SNP, race, and cycle 1 day 15 (C1D15) absolute neutrophil count (ANC) data were available for 652 patients. Univariate and multivariable analyses evaluated associations between SNPs, patient baseline characteristics, and early occurrence of grade 3\/4 neutropenia. Analyses were stratified by Asian (n =\u2009122) and non-Asian (n =\u2009530) ethnicity. Median progression-free survival (mPFS) was estimated using the Kaplan-Meier method. The effect of genetic variants on palbociclib pharmacokinetics was analyzed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>ABCB1 and ERCC1_rs11615 SNP frequencies differed between Asian and non-Asian patients. Multivariable analysis showed that low baseline ANC was a strong independent risk factor for C1D15 grade 3\/4 neutropenia regardless of race (Asians: odds ratio [OR], 6.033, 95% confidence interval [CI], 2.615\u221213.922, p &amp;lt; .0001; Non-Asians: OR, 6.884, 95% CI, 4.138\u221211.451, p &amp;lt; .0001). ABCB1_rs1128503 (C\/C vs. T\/T: OR, 0.57, 95% CI, 0.311\u22121.047, p = .070) and ERCC1_rs11615 (A\/A vs. G\/G: OR, 1.75, 95% CI, 0.901\u22123.397, p = .098) were potential independent risk factors for C1D15 grade 3\/4 neutropenia in non-Asian patients. Palbociclib mPFS was consistent across genetic variants; exposure was not associated with ABCB1 genotype.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This is the first comprehensive assessment of pharmacogenetic data in relationship to exposure to a CDK4\/6 inhibitor. Pharmacogenetic testing may inform about potentially increased likelihood of patients developing severe neutropenia (NCT01740427, NCT01942135).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Implications for Practice<\/jats:title>\n                  <jats:p>Palbociclib plus endocrine therapy improves hormone receptor\u2013positive\/human epidermal growth factor receptor 2\u2013negative advanced breast cancer outcomes, but is commonly associated with neutropenia. Genetic variants in ABCB1 may influence palbociclib exposure, and in ERCC1 are associated with chemotherapy-induced severe neutropenia. Here, the associations of single nucleotide polymorphisms in these genes and baseline characteristics with neutropenia were assessed. Low baseline absolute neutrophil count was a strong risk factor (p &amp;lt; .0001) for grade 3\/4 neutropenia. There was a trend indicating that ABCB1_rs1128503 and ERCC1_rs11615 were potential risk factors (p &amp;lt; .10) for grade 3\/4 neutropenia in non-Asian patients. Pharmacogenetic testing could inform clinicians about the likelihood of severe neutropenia with palbociclib.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1002\/onco.13811","type":"journal-article","created":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T19:58:20Z","timestamp":1620331100000},"page":"e1143-e1155","source":"Crossref","is-referenced-by-count":29,"title":["Evaluation of the Association of Polymorphisms With Palbociclib-Induced Neutropenia: Pharmacogenetic Analysis of PALOMA-2\/-3"],"prefix":"10.1093","volume":"26","author":[{"given":"Hiroji","family":"Iwata","sequence":"first","affiliation":[{"name":"Aichi Cancer Center Hospital, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4967-0382","authenticated-orcid":false,"given":"Yoshiko","family":"Umeyama","sequence":"additional","affiliation":[{"name":"Pfizer R&D Japan, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Pfizer Inc, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Zhang","sequence":"additional","affiliation":[{"name":"Pfizer Inc, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Schnell","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Mori","sequence":"additional","affiliation":[{"name":"Pfizer R&D Japan, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Fletcher","sequence":"additional","affiliation":[{"name":"Breast Cancer Now Toby Robins Research Centre, The Institute for Cancer Research, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Claude","family":"Marshall","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Groton, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jillian G.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Groton, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda S.","family":"Wood","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Groton, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Toi","sequence":"additional","affiliation":[{"name":"Kyoto University Graduate School of Medicine, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard S.","family":"Finn","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine, University of California Los Angeles, Santa Monica, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas C.","family":"Turner","sequence":"additional","affiliation":[{"name":"Breast Cancer Now Toby Robins Research Centre, The Institute for Cancer Research, London, United Kingdom"},{"name":"Royal Marsden Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia Huang","family":"Bartlett","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Cristofanilli","sequence":"additional","affiliation":[{"name":"Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,6,7]]},"reference":[{"key":"2022020214132281800_onco13811-bib-0001","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1200\/JCO.2016.67.1487","article-title":"Endocrine therapy for hormone receptor\u2013positive metastatic breast cancer: American Society of Clinical Oncology guideline","volume":"34","author":"Rugo","year":"2016","journal-title":"J Clin Oncol"},{"key":"2022020214132281800_onco13811-bib-0002","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1093\/annonc\/mdy192","article-title":"4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)","volume":"29","author":"Cardoso","year":"2018","journal-title":"Ann Oncol"},{"key":"2022020214132281800_onco13811-bib-0003","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/jnci\/djy109","article-title":"Long-term pooled safety analysis of palbociclib in combination with endocrine therapy for HR+\/HER2\u2013 advanced breast cancer","volume":"111","author":"Di\u00e9ras","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"2022020214132281800_onco13811-bib-0004","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"key":"2022020214132281800_onco13811-bib-0005","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1505270","article-title":"Palbociclib in hormone-receptor\u2013positive advanced breast cancer","volume":"373","author":"Turner","year":"2015","journal-title":"N Engl J Med"},{"key":"2022020214132281800_onco13811-bib-0006","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","article-title":"Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): Final analysis of the multicentre, double-blind, phase 3 randomised controlled trial","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol"},{"key":"2022020214132281800_onco13811-bib-0007","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s10549-018-05125-4","article-title":"Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up","volume":"174","author":"Rugo","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"2022020214132281800_onco13811-bib-0008","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","article-title":"The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): A randomised phase 2 study","volume":"16","author":"Finn","year":"2015","journal-title":"Lancet Oncol"},{"key":"2022020214132281800_onco13811-bib-0009","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1158\/1078-0432.CCR-15-1421","article-title":"Mechanistic investigation of bone marrow suppression associated with palbociclib and its differentiation from cytotoxic chemotherapies","volume":"22","author":"Hu","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2022020214132281800_onco13811-bib-0010","volume-title":"Full Prescribing Information, Pfizer Inc","author":"IBRANCE capsules (palbociclib)","year":"2019"},{"key":"2022020214132281800_onco13811-bib-0011","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/FPC.0b013e3283385a1c","article-title":"Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein)","volume":"21","author":"Hodges","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"2022020214132281800_onco13811-bib-0012","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/mc.2940130302","article-title":"Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy","volume":"13","author":"Wacher","year":"1995","journal-title":"Mol Carcinog"},{"key":"2022020214132281800_onco13811-bib-0013","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1158\/0008-5472.CAN-15-1410","article-title":"Cytochrome P450 allele CYP3A7*1C associates with adverse outcomes in chronic lymphocytic leukemia, breast, and lung cancer","volume":"76","author":"Johnson","year":"2016","journal-title":"Cancer Res"},{"key":"2022020214132281800_onco13811-bib-0014","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000005151","article-title":"Drug-related genetic polymorphisms affecting severe chemotherapy-induced neutropenia in breast cancer patients: A hospital-based observational study","volume":"95","author":"Tsuji","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"2022020214132281800_onco13811-bib-0015","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1073\/pnas.97.7.3473","article-title":"Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo","volume":"97","author":"Hoffmeyer","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022020214132281800_onco13811-bib-0016","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.4161\/cc.26309","article-title":"ERCC1 function in nuclear excision and interstrand crosslink repair pathways is mediated exclusively by the ERCC1-202 isoform","volume":"12","author":"Friboulet","year":"2013","journal-title":"Cell Cycle"},{"key":"2022020214132281800_onco13811-bib-0017","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s10147-018-1353-9","article-title":"Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients","volume":"24","author":"Mukai","year":"2019","journal-title":"Int J Clin Oncol"},{"key":"2022020214132281800_onco13811-bib-0018","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/s10147-018-1359-3","article-title":"Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients","volume":"24","author":"Masuda","year":"2019","journal-title":"Int J Clin Oncol"},{"key":"2022020214132281800_onco13811-bib-0019","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JGO.2016.008318","article-title":"PALOMA-3: Phase III trial of fulvestrant with or without palbociclib in premenopausal and postmenopausal women with hormone receptor\u2013positive, human epidermal growth factor receptor 2\u2013negative metastatic breast cancer that progressed on prior endocrine therapy\u2013Safety and efficacy in Asian patients","volume":"3","author":"Iwata","year":"2017","journal-title":"J Glob Oncol"},{"key":"2022020214132281800_onco13811-bib-0020","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1634\/theoncologist.2019-0019","article-title":"Palbociclib with letrozole in postmenopausal women with ER+\/HER2- advanced breast cancer: Hematologic safety analysis of the randomized PALOMA-2 trial","volume":"24","author":"Di\u00e9ras","year":"2019","journal-title":"The Oncologist"},{"key":"2022020214132281800_onco13811-bib-0021","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s12282-019-00970-7","article-title":"Neutropenia management with palbociclib in Japanese patients with advanced breast cancer","volume":"26","author":"Masuda","year":"2019","journal-title":"Breast Cancer"},{"key":"2022020214132281800_onco13811-bib-0022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrd.2016.234","article-title":"Genome-wide association studies of drug response and toxicity: An opportunity for genome medicine","volume":"16","author":"Giacomini","year":"2017","journal-title":"Nat Rev Drug Discov"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/onco.13811","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/onco.13811","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/7\/e1143\/42367420\/oncolo_26_7_e1143.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/7\/e1143\/42367420\/oncolo_26_7_e1143.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T14:14:46Z","timestamp":1643811286000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/26\/7\/e1143\/6510484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,7]]},"references-count":22,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,6,7]]},"published-print":{"date-parts":[[2021,7,1]]}},"URL":"https:\/\/doi.org\/10.1002\/onco.13811","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,7,1]]},"published":{"date-parts":[[2021,6,7]]}}}